Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03305874 · ClinicalTrials.gov registry record
Automated Prediction and Prevention of Contrast Induced Nephropathy After Cardiac Catheterization
A clinical trial, sponsored by University of Chicago.
- Completed
- Registry status
- 5
- Enrollment target
NCT03305874: Completed study, sponsored by University of Chicago.
NCT03305874 is a clinical trial that has completed, run by University of Chicago. The registered enrollment target is 5 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03305874 has completed, sponsored by University of Chicago.
- COMPLETED
- Registry status
- 5 participants
- Enrollment target
Study Summary
Contrast agent is typically used during routine cardiac intervention in order to enhance the imaging necessary to perform the procedure. Using this contrast agent could lead to kidney injury, called contrast induced nephropathy (CIN). Currently, the methods used to reduce the risk of CIN include reducing the amount of contrast agent used and using a hydration strategy during procedure. A computer-based risk tool has been developed which reports a risk score for the likelihood a person undergoing cardiac intervention gets CIN and a proposed corresponding hydration strategy to reduce the risk of CIN. The purpose of this study is to determine whether the rate of CIN decreases when the treating physician has access to this risk tool during the procedure.
Primary Outcome
increase in serum creatinine of ≥0.3 mg/dL or ≥50% from the value before the procedure to the highest post-procedure value on days 1-4
Interventions
- OTHER Exposure to CBCIN risk score
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 5 participants |
| Start Date | 2018-03-07 |
| Est. Completion | 2023-07-17 |
What the finished NCT03305874 record still lists
NCT03305874 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 5 participants, a relatively small participant target.
The record links to 0 conditions, and to 1 intervention - of which Exposure to CBCIN risk score is the first listed.
NCT03305874 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03305874 about?
NCT03305874 is a clinical study titled "Automated Prediction and Prevention of Contrast Induced Nephropathy After Cardiac Catheterization". Contrast agent is typically used during routine cardiac intervention in order to enhance the imaging necessary to perform the procedure. Using this contrast agent could lead to kidney injury, called contrast induced nephropathy (CIN). Currently, the methods used to reduce the risk of CIN include red...
What is the current status of trial NCT03305874?
This trial is currently completed. The enrollment target is 5 participants. The study started on 2018-03-07. Estimated completion is 2023-07-17.
What interventions are being tested in trial NCT03305874?
The interventions under investigation include: Exposure to CBCIN risk score (OTHER).
Who is sponsoring clinical trial NCT03305874?
This trial is sponsored by University of Chicago, which has 796 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI